<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Endocrinology/Diabetes/GLP1%20Agonists/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>GLP-1 Receptor Agonists - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "GLP-1 Receptor Agonists", url: "#_top", children: [
          ]},
          {title: "CV Outcomes of GLP-1 RA", url: "#cv-outcomes-of-glp-1-ra", children: [
              {title: "Mechanisms of MACE Outcomes", url: "#mechanisms-of-mace-outcomes" },
          ]},
          {title: "Kidney Outcomes of GLP-1 RA", url: "#kidney-outcomes-of-glp-1-ra", children: [
          ]},
          {title: "Obesity Outcomes of GLP-1 RA", url: "#obesity-outcomes-of-glp-1-ra", children: [
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Insulin%20Neuritis/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Insulin%20Neuritis/" class="btn btn-xs btn-link">
        Treatment-induced neuropathy of diabetes (TIND)
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Calcium%20Disorders/Hypocalcemia/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Calcium%20Disorders/Hypocalcemia/" class="btn btn-xs btn-link">
        Hypocalcemia
      </a>
    </div>
    
  </div>

    

    <h1 id="glp-1-receptor-agonists">GLP-1 Receptor Agonists</h1>
<p>GLP1 agonists are diabetes medications with growing applications in cardiovascular disease, bariatric medicine. GLP-1 RA were initially developed as glucose-lowering drugs because activation of the GLP-1 receptor by these agents leads to a reduction in blood glucose and an improvement in postprandial glucose metabolism. By stimulating GLP-1R in hypothalamic neurons, GLP-1 RA additionally induce satiety and lead to weight loss. In contrast with GLP-1 RA, DPP4 inhibitors did not reduce MACE in large CVOTs.</p>
<p><img alt="" src="../_attachments/circulationaha.122.059595.fig01.jpg" /></p>
<h1 id="cv-outcomes-of-glp-1-ra">CV Outcomes of GLP-1 RA</h1>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Trial (Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lixisenatide</td>
<td>ELIXA</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>LEADER</td>
</tr>
<tr>
<td>Semaglutide</td>
<td>SUSTAIN 6</td>
</tr>
<tr>
<td>Exenatide</td>
<td>EXSCEL</td>
</tr>
<tr>
<td>Albiglutide</td>
<td>HARMONY OUTCOMES</td>
</tr>
<tr>
<td>Dulaglutide</td>
<td>REWIND</td>
</tr>
<tr>
<td>Semaglutide</td>
<td>PIONEER-6</td>
</tr>
<tr>
<td>Efpeglenatide</td>
<td>AMPLITUDE-O</td>
</tr>
</tbody>
</table>
<p>A meta-analysis of these 8 CVOTs revealed a 14% reduction in the primary outcome of the 3-component MACE (cardiovascular death, nonfatal MI, and nonfatal stroke; number needed to treat, 65), with moderate heterogeneity. These results improve to a 15% reduction in MACE with low heterogeneity (14.9%) after removal of the ELIXA trial.</p>
<table>
<thead>
<tr>
<th style="text-align: left;"></th>
<th style="text-align: left;">Main analysis with all 8 CVOTs (HR; I2)</th>
<th style="text-align: left;">Sensitivity analyses minus ELIXA (HR; I2)</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: left;">MACE</td>
<td style="text-align: left;">0.86 (0.80 to 0.93) 45%</td>
<td style="text-align: left;">0.85 (0.80 to 0.90) 15%</td>
</tr>
<tr>
<td style="text-align: left;">CV death</td>
<td style="text-align: left;">0.87 (0.80 to 0.94) 13%</td>
<td style="text-align: left;">0.85 (0.78 to 0.93) 12%</td>
</tr>
<tr>
<td style="text-align: left;">MI</td>
<td style="text-align: left;">0.90 (0.83 to 0.98) 27%</td>
<td style="text-align: left;">0.88 (0.81 to 0.96) 16%</td>
</tr>
<tr>
<td style="text-align: left;">All-cause mortality</td>
<td style="text-align: left;">0.88 (0.82 to 0.94) 10%</td>
<td style="text-align: left;">0.87 (0.81 to 0.94) 17%</td>
</tr>
<tr>
<td style="text-align: left;">Incident HHF</td>
<td style="text-align: left;">0.89 (0.82 to 0.98) 3%</td>
<td style="text-align: left;">0.88 (0.79 to 0.98) 12%</td>
</tr>
<tr>
<td style="text-align: left;">Kidney composite (+ albuminuria)</td>
<td style="text-align: left;">0.79 (0.73 to 0.87) 48%</td>
<td style="text-align: left;">0.78 (0.71 to 0.87) 57%</td>
</tr>
<tr>
<td style="text-align: left;">Worsening kidney function (eGFR)</td>
<td style="text-align: left;">0.86 (0.72 to 1.02) 43%</td>
<td style="text-align: left;">0.82 (0.69 to 0.98) 40%</td>
</tr>
</tbody>
</table>
<h2 id="mechanisms-of-mace-outcomes">Mechanisms of MACE Outcomes</h2>
<ol>
<li>GLP-1 RA lead to a reduction in systolic blood pressure of 2 to 6 mm Hg</li>
<li>GLP-1 RA have been shown to modestly reduce total cholesterol, LDL cholesterol, and triglycerides</li>
<li>GLP-1 RA lead to a reduction of HbA1c between 0.8% and 1.5%.</li>
<li>GLP-1 RA lead to a modest reduction in weight between 2.5 and 4 kg</li>
</ol>
<div class="admonition note">
<p class="admonition-title">Note</p>
<p>GLP-1 RA mainly reduce ASCVD-associated outcomes such as MI, stroke, and cardiovascular death.</p>
</div>
<h1 id="kidney-outcomes-of-glp-1-ra">Kidney Outcomes of GLP-1 RA</h1>
<p>Various GLP-1 RA have been shown to reduce albuminuria/ progression of albuminuria, an established surrogate parameter for worsening kidney function, and a meta-analysis of GLP-1 RA CVOTs suggests that a combined kidney outcome that includes progression of albuminuria was reduced by 21% to 22%.</p>
<p>Based on the LEADER and SUSTAIN-6 trials, semaglutide and liraglutide may have renal-protective effects especially in patients with pre-existing CKD.</p>
<p>The <a href="https://clinicaltrials.gov/study/NCT03819153">FLOW trial</a> is currently examining weekly semaglutide in patients with CKD.</p>
<h1 id="obesity-outcomes-of-glp-1-ra">Obesity Outcomes of GLP-1 RA</h1>
<p>Semaglutide, liraglutide are approved for use in obesity.</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Trial</th>
<th>Effect</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semaglutide</td>
<td>STEP 1, STEP 2, STEP 8</td>
<td>weight loss in individuals considered overweight or with obesity, with or without diabetes.</td>
<td>Once-weekly SC injection +/- DM2</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>SCALE</td>
<td>weight loss in individuals considered overweight or with obesity, with or without diabetes.</td>
<td>Once-daily SC injection. +/- DM2</td>
</tr>
<tr>
<td>Tirzepatide (novel GLP-1 and GIP receptor agonist)</td>
<td>SURMOUNT-2</td>
<td>weight loss in obesity +/- DM2, greater effect than semaglutide and placebo</td>
<td></td>
</tr>
<tr>
<td># Guideline Recommendations for GLP-1 RA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. The 2019 European Society of Cardiology guidelines on diabetes, prediabetes, and CVD recommend treatment with GLP-1 RA (or SGLT2i) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) or high/very high risk (high-risk patients, diabetes duration ≥10 years without target organ damage plus any other additional risk factor; very high–risk patients, diabetes and established CVD, evidence of target organ damage [proteinuria, eGFR &lt;30 mL/min/1.73 m2, left ventricular hypertrophy, or retinopathy], 3 or more major risk factors, or early-onset type 1 diabetes [of long duration [&gt;20 years]) to reduce cardiovascular events.]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. 2020 report of the American College of Cardiology Solution Set Oversight Committee on novel therapies for cardiovascular risk reduction in patients with T2D recommends initiating a patient-clinician discussion about the use of an SGLT2i and/or a GLP-1 RA with demonstrated cardiovascular benefit for patients with T2D who have or who are at very high risk for clinical atherosclerotic cardiovascular disease, HF, and/or diabetic kidney disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. 2022 American Diabetes Association “Standards of Medical Care in Diabetes” recommend treatment with GLP-1 RA or SGLT2i in T2D with ASCVD or high risk (such as patients ≥55 years of age with coronary, carotid, or lower-extremity artery stenosis &gt;50% or left ventricular hypertrophy), independently of baseline HbA1c, individualized HbA1c target, or metformin use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># Summary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In general, GLP-1 RA are indicated for those patients who:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ol>
<li>Have DM2, and:<ol>
<li>Established ASCVD</li>
<li>High-risk to very-high-risk for ASCVD<ol>
<li>Duration of DM2 &gt; 10 years</li>
<li>Proteinuria, eGFR &lt; 30</li>
<li>LVH</li>
<li>Retinopathy</li>
<li>Heart failure</li>
<li>Carotid or peripheral arterial disease &gt; 50%</li>
</ol>
</li>
</ol>
</li>
<li>Obese (in conjunction with lifestyles changes and consideration for bariatric surgery)<ol>
<li>BMI &gt;= 30</li>
<li>BMI &gt;= 27 with adiposity-related complications (see <a href="../../Obesity/Obesity/">Obesity</a>)</li>
<li>BMI &gt;= 27 with DM2</li>
</ol>
</li>
</ol>
<h1 id="references">References</h1>
<ol>
<li><a href="https://www-ahajournals-org.libaccess.lib.mcmaster.ca/doi/full/10.1161/CIRCULATIONAHA.122.059595#d1e1515">GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation</a></li>
<li><a href="https://www.uptodate.com/contents/obesity-in-adults-drug-therapy">Obesity in adults: Drug therapy - UpToDate</a></li>
<li><a href="https://obesitycanada.ca/guidelines/pharmacotherapy/">Pharmacotherapy in Obesity Management - Obesity Canada</a></li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Insulin%20Neuritis/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Insulin%20Neuritis/" class="btn btn-xs btn-link">
        Treatment-induced neuropathy of diabetes (TIND)
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Calcium%20Disorders/Hypocalcemia/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Calcium%20Disorders/Hypocalcemia/" class="btn btn-xs btn-link">
        Hypocalcemia
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>